(Bloomberg) – Novartis AG applied for U.S. regulatory approval for two drugs to treat smoker’s cough that analysts estimate could generate an additional $1.4 billion in annual sales for the Swiss drugmaker. Third-phase clinical tests for QVA149 and NVA237 showed “positive” results for the treatment of chronic obstructive pulmonary disorder, or smoker’s cough, Basel-based Novartis said today […]
Join the fight for freedom
Be the first to know: Stories from The Washington Informer in your inbox each weekday.